Human papillomavirus type 16 E5 oncoprotein as a new target for cervical cancer treatment
- 17 July 2010
- journal article
- review article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 80 (12) , 1930-1935
- https://doi.org/10.1016/j.bcp.2010.07.013
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Science and Technology (2009-0093820)
- Ministry of Education, Science and Technology (R31-2008-000-10056-0)
This publication has 76 references indexed in Scilit:
- A Role for HPV16 E5 in Cervical CarcinogenesisCancer Research, 2010
- Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2009
- Angiogenesis as a strategic target for ovarian cancer therapyNature Clinical Practice Oncology, 2008
- Treating Cancer as an Infectious Disease—Viral Antigens as Novel Targets for Treatment and Potential Prevention of Tumors of Viral EtiologyPLOS ONE, 2007
- Human Papillomavirus 16 E5 Oncogene Contributes to Two Stages of Skin CarcinogenesisCancer Research, 2007
- Human papillomavirus type distribution in invasive cervical cancer and high‐grade cervical lesions: A meta‐analysis updateInternational Journal of Cancer, 2007
- Overexpression of Human Papillomavirus Type 16 Oncoproteins Enhances Hypoxia-Inducible Factor 1α Protein Accumulation and Vascular Endothelial Growth Factor Expression in Human Cervical Carcinoma CellsClinical Cancer Research, 2007
- Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysisBritish Journal of Cancer, 2003
- The Hallmarks of CancerCell, 2000
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisPublished by Elsevier ,1996